Egetis Therapeutics AB (publ) announced the recruitment of Anny Bedard as President of Egetis North America and as a member of the Company's leadership team. Ms. Bedard has over 25 years of international experience in both established and entrepreneurial biopharmaceutical companies, across a broad set of strategic and operating functions in diverse business environments. Her key expertise lies in new market entry, strategic planning, alliance management, country and regional management, product launch, sales and business development.

She has 15 years of experience in the Rare Disease space. Ms. Bedard will be responsible for establishing and maintaining a successful presence of Egetis and its products in the United States and Canada, including establishing the infrastructure for Egetis North America, developing relationships with key national stakeholders, and recruiting a highly effective team to support all initiatives necessary for the successful launch of Emcitate in 2024. Sara Melton, former President of Egetis North America, will leave the Company to pursue other opportunities.

Prior to joining Egetis Ms. Bedard served as President of ABio Consulting, where she focused on rare diseases. Anny advised and supported strategic decision making for multiple US and EU biopharma companies across diverse therapeutic areas, technologies and markets to deliver growth at the product, franchise and corporate level. Before that she was Vice President, Head of International Business, at Sarepta Therapeutics where she designed and executed Sarepta's entry into Latin America and Asia Pacific.

At Shire, she established and led the company's successful growth in multiple geographies and launched the company's leading brands in Fabry, Gaucher, Hunter Syndrome and hereditary angioedema. Ms. Bedard started her career at Fournier Pharma and worked at Serono US before joining Shire and Sarepta. She has a Masters degree in cellular and molecular biology from Laval University in Quebec, Canada.